Bioqube Ventures is a global life sciences venture capital firm with offices in Belgium and the United States, investing in companies developing first- or best-in-class therapeutics from inception through early clinical milestones.
55% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 3 prior). Average disclosed round size is $85.2M (across 4 rounds with reported amounts).
Portfolio
10
Fund Size
$66M
Top Stage
Series A
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| PPrimmune Therapeutics | Series B | $23.3M | Jan 2026 |
 Spica Therapeutics | Seed | — | Jun 2025 |
| SSynOx Therapeutics | Unknown | $92M | Oct 2024 |
 CatalYm | Series D | $150M | Jul 2024 |
 Anavo Therapeutics | Seed | — | May 2023 |
| AAnavo | Seed | — | May 2023 |
 Tridek-One | Series A | — | Sep 2022 |
| TTridek-One | Unknown | — | Sep 2022 |
 Egle Therapeutics | Series A | — | Oct 2021 |
| TTridek-One | Unknown | — | Jan 2019 |
 Actithera | Series A | $75.5M | — |
Top Co-Investors
Bpifrance4 shared
AdBio partners3 shared
Pureos Bioventures3 shared
M Ventures3 shared
EQT Life Sciences2 shared
MRL Ventures Fund2 shared
INKEF Capital2 shared
Gilde Healthcare2 shared
4BIO Capital1 shared
Investinor1 shared
Sofinnova Partners1 shared
Surveyor Capital1 shared
Hadean Ventures1 shared
Hercules Capital, Inc.1 shared
Forbion1 shared
HealthCap1 shared
Jeito Capital1 shared
Omega Funds1 shared
Canaan Partners1 shared
Brandon Capital1 shared
Last updated: 8 September 2026